Every 10-Q that Clarivate Plc (CLVT) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow CLVT and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full CLVT filings page.
Clarivate Plc reported softer results for the quarter ended June 30, 2026. Revenue was $587.3 million, down 5% year over year, with declines across Academia & Government, Intellectual Property, and Life Sciences & Healthcare. A non‑cash goodwill impairment of $221.7 million in the LS&H segment drove a quarterly net loss of $268.6 million and a year‑to‑date loss of $308.8 million.
Despite lower revenue, Adjusted EBITDA was $247.2 million in Q2 with a 42.1% margin, and first‑half operating cash flow was $233.4 million, yielding Free cash flow of $122.9 million. Total debt declined to $4.25 billion after redeeming $100 million of 2026 notes and repurchasing portions of 2028 and 2029 notes. In July 2026 the company agreed to sell its LS&H business for $600.0 million (mostly cash), and management states it plans to use proceeds to reduce debt and focus on the A&G and IP segments; LS&H will be reported as a discontinued operation beginning in the third quarter of 2026.
Clarivate Plc reported a Q1 2026 net loss of $40.2 million on revenue of $585.5 million, down 1.4% year over year. Operating income improved to $30.2 million from a $20.8 million loss as cost of revenues fell 7% and restructuring charges roughly halved.
Adjusted EBITDA rose to $241.2 million with a 41.2% margin, up from 39.3%. Net cash from operating activities was $134.7 million and free cash flow was $78.9 million. The company ended the quarter with $242.2 million in cash and $4.3 billion of debt, and repurchased 7 million shares for $18.1 million. Clarivate is pursuing a potential sale of its Life Sciences & Healthcare segment to sharpen focus on its Academia & Government and Intellectual Property businesses.
Clarivate (CLVT) reported Q3 2025 results with revenue of $623.1 million, essentially flat year over year. Income from operations improved to $44.0 million from $21.7 million as cost controls offset higher depreciation and amortization. Net loss narrowed to $28.3 million from $65.6 million, and interest expense declined to $68.5 million from $72.2 million.
Year to date, revenue was $1,838.2 million versus $1,893.7 million, reflecting divestitures and product wind-downs. Segment Adjusted EBITDA totaled $252.4 million in the quarter. Operating cash flow reached $468.6 million for the nine months, supporting capital expenditures of $192.5 million and share repurchases of $149.5 million for approximately 34.8 million shares. Long-term debt was $4,419.0 million, down from $4,518.7 million, aided by redeeming $600.0 million of 2026 senior secured notes and adding a $500.0 million Tranche 2 term loan. Ordinary shares outstanding were 661,435,069 as of September 30, 2025.